The lab analyst performs a liquid biopsy using a serum specimen to identify cell–free DNA (cfDNA) for a genomic sequence analysis panel to identify changes known to impact diagnosis and treatment of solid organ tumors. The test evaluates nucleic acid sequence variants, copy number variants, and microsatellite instability (MSI), which is an indicator of how likely the cells are to mutate.
For clinical responsibility, terminology, tips and additional info
start codify free trial.